{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:44:08Z","timestamp":1782362648961,"version":"3.54.5"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9,1]]},"DOI":"10.1086\/519253","type":"journal-article","created":{"date-parts":[[2007,8,8]],"date-time":"2007-08-08T16:02:41Z","timestamp":1186588961000},"page":"S153-S162","source":"Crossref","is-referenced-by-count":21,"title":["Increasing the Efficiency of Clinical Trials of Antimicrobials: The Scientific Basis of Substantial Evidence of Effectiveness of Drugs"],"prefix":"10.1093","volume":"45","author":[{"given":"John H.","family":"Powers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,9,1]]},"reference":[{"key":"key\n\t\t\t\t20171014032459_ref1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2307\/3563623","article-title":"Scientific value and validity as ethical requirements for research: a proposed explication","volume":"9","author":"Freedman","year":"1987","journal-title":"IRB"},{"key":"key\n\t\t\t\t20171014032459_ref2","volume-title":"Federal Food, Drug, and Cosmetic Act. New drugs. US Code title 21, section 351: chapter V, subchapter A, section 505","author":"US Government Printing Office","year":"2007"},{"key":"key\n\t\t\t\t20171014032459_ref3","first-page":"373","article-title":"Clinical trials of patulin in the common cold","volume":"ii","author":"Medical Research Council","year":"1944","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014032459_ref4","first-page":"769","article-title":"Streptomycin treatment of pulmonary tuberculosis","volume":"ii","author":"Medical Research Council","year":"1948","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20171014032459_ref5","volume-title":"Scientific method: an historical and scientific introduction","author":"Gower","year":"1997"},{"key":"key\n\t\t\t\t20171014032459_ref6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ije\/dyh192","article-title":"Commentary: hormone replacement therapy and coronary heart disease: four lessons","volume":"33","author":"Petitti","year":"2004","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20171014032459_ref7","first-page":"1643","article-title":"Development of drug law, regulations, and guidance in the United States","author":"Temple","year":"1995","journal-title":"Principles of pharmacology: basic concepts and clinical applications"},{"key":"key\n\t\t\t\t20171014032459_ref8","author":"Pharmaceutical Manufacturers Association v Richardson","year":"1970"},{"key":"key\n\t\t\t\t20171014032459_ref9","first-page":"944","volume-title":"Federal Reporter","author":"Upjohn Co v Finch","year":"1970"},{"key":"key\n\t\t\t\t20171014032459_ref10","author":"Weinberger v Hynson, Westcott, and Dunning","year":"1973"},{"key":"key\n\t\t\t\t20171014032459_ref11","volume-title":"Legal definition of substantial evidence","author":"'Lectric Law Library"},{"key":"key\n\t\t\t\t20171014032459_ref12","author":"United States v Rutherford","year":"1979"},{"key":"key\n\t\t\t\t20171014032459_ref13","volume-title":"Applications for FDA approval to market a new drug: adequate and well-controlled studies. US Code title 21, section 314.126","author":"US Government Printing Office","year":"2006"},{"key":"key\n\t\t\t\t20171014032459_ref14","first-page":"751","article-title":"Shifting goalposts in antibiotic approval","volume-title":"Lancet Infect Dis","year":"2006"},{"key":"key\n\t\t\t\t20171014032459_ref15","volume-title":"ICH harmonised tripartite guideline: statistical principles for clinical trials. ICH E-9","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)","year":"1998"},{"key":"key\n\t\t\t\t20171014032459_ref16","volume-title":"ICH harmonised tripartite guideline: choice of control group and related issues in clinical trials. ICH E-10","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)","year":"2000"},{"key":"key\n\t\t\t\t20171014032459_ref17","volume-title":"Center for Drug Evaluation and Research guidances","author":"US Food and Drug Administration"},{"key":"key\n\t\t\t\t20171014032459_ref18","volume-title":"US Code title 21, part 201.57","author":"Specific requirements on content and format of labeling for human prescription drugs","year":"2006"},{"key":"key\n\t\t\t\t20171014032459_ref19","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1086\/425922","article-title":"Empirical antifungal therapy in febrile neutropenic patients: caution about composite end points and the perils of P values","volume":"39","author":"Powers","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014032459_ref20","first-page":"619","article-title":"Interpreting the results of clinical trials on antimicrobial agents","volume-title":"Principles and practice of infectious diseases","author":"Powers","year":"2005","edition":"6"},{"key":"key\n\t\t\t\t20171014032459_ref21","first-page":"27","article-title":"Design and interpretation of clinical trials","volume-title":"Statistical issues in drug development","author":"Senn","year":"1997"},{"key":"key\n\t\t\t\t20171014032459_ref22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1472-8206.2003.00162.x","article-title":"The pros and cons of noninferiority trials","volume":"17","author":"Pocock","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"key\n\t\t\t\t20171014032459_ref23","volume-title":"Clinical trial design in studies of acute bacterial sinusitis. Anti-Infective Drugs Advisory Committee Meeting","author":"US Food and Drug Administration","year":"2003"},{"key":"key\n\t\t\t\t20171014032459_ref24","volume-title":"Antimicrobial Resistance & Drug Development FDA\/IDSA\/ISAPWorking Group presentations and transcripts","author":"US Food and Drug Administration","year":"2004"},{"key":"key\n\t\t\t\t20171014032459_ref25","volume-title":"Transcript of the IDSA\/PhRma\/ FDA Working Group Meeting, November 19\u201320","author":"US Food and Drug Administration","year":"2002"},{"key":"key\n\t\t\t\t20171014032459_ref26","volume-title":"Transcripts of the Anti-Infective Drugs Advisory Committee: gemifloxacin NDA 21\u2013158\/S006.","author":"US Food and Drug Administration","year":"2006"},{"key":"key\n\t\t\t\t20171014032459_ref27","volume-title":"Transcripts of the Joint Meeting of the Anti-Infective Drugs and Drug Safety and Risk Management Advisory Committees: telithromycin NDA 21-144.","author":"US Food and Drug Administration","year":"2006"},{"key":"key\n\t\t\t\t20171014032459_ref28","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1086\/508455","article-title":"Issues related to the design and interpretation of clinical trials for salvage therapy for invasive mold infections","volume":"43","author":"Almyroudis","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014032459_ref29","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1086\/508468","article-title":"Salvage therapy trials in invasive fungal disease: challenges and opportunities","volume":"43","author":"Powers","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014032459_ref30","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"key\n\t\t\t\t20171014032459_ref31","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/01.inf.0000092637.66762.c6","article-title":"Correlation between bacteriologic and clinical endpoints in trials of acute otitis media","volume":"22","author":"Johann","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"12 Pt 2","key":"key\n\t\t\t\t20171014032459_ref32","doi-asserted-by":"crossref","first-page":"109S","DOI":"10.1592\/phco.2005.25.12part2.109S","article-title":"Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials","volume":"25","author":"Powers","year":"2005","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171014032459_ref33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171014032459_ref34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/CVM-1-1-019","article-title":"Noninferiority trials","volume":"1","author":"Snapinn","year":"2000","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"key\n\t\t\t\t20171014032459_ref35","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything all right? Interpreting zero numerators","volume":"249","author":"Hanley","year":"1983","journal-title":"JAMA"},{"issue":"Suppl 4","key":"key\n\t\t\t\t20171014032459_ref36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1465-0691.2004.1007.x","article-title":"Antimicrobial drug development\u2014the past, the present, and the future","volume":"10","author":"Powers","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171014032459_ref37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/archpedi.159.10.943","article-title":"Association of amoxicillin use during early childhood with developmental tooth enamel defects","volume":"159","author":"Hong","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"key\n\t\t\t\t20171014032459_ref38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1378\/chest.126.1.314","article-title":"Linezolid and vancomycin for methicillin- resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses","volume":"126","author":"Powers","year":"2004","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171014032459_ref39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM199708213370810","article-title":"The promise and problems of meta-analysis","volume":"337","author":"Bailar","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014032459_ref40","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(06)69606-2","article-title":"Antibiotics for acute otitis media: a meta-analysis with individual patient data","volume":"368","author":"Rovers","year":"2006","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014032459_ref41","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jama.1995.03520360071042","article-title":"Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis","volume":"273","author":"Saint","year":"1995","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171014032459_ref42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJM199708213370806","article-title":"Discrepancies between meta-analyses and subsequent large randomized, controlled trials","volume":"337","author":"LeLorier","year":"1997","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/45\/Supplement_2\/S153\/20907731\/45-Supplement_2-S153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T03:25:07Z","timestamp":1507951507000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/45\/Supplement_2\/S153\/285790\/Increasing-the-Efficiency-of-Clinical-Trials-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,1]]},"references-count":42,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2007,9,1]]},"published-print":{"date-parts":[[2007,9,1]]}},"URL":"https:\/\/doi.org\/10.1086\/519253","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,9,1]]},"published":{"date-parts":[[2007,9,1]]}}}